VEGFA and hyperlipidemia: Compared to the control group, patients with intravitreal VEGF inhibitor treatment had lower mean glycated hemoglobin (HbA1c) levels (p = 0.02), higher prevalence of hyperlipidemia (p = 0.01), and higher prevalence of contrast medium exposure (p < 0.01).